-+ 0.00%
-+ 0.00%
-+ 0.00%

Aclaris publishes corporate presentation outlining inflammatory and immunology pipeline, 2026 clinical catalysts

PUBT·07/15/2026 17:38:34
Listen to the news
Aclaris publishes corporate presentation outlining inflammatory and immunology pipeline, 2026 clinical catalysts
  • Aclaris outlined three 2026 pipeline catalysts across its inflammation and immunology portfolio, centered on TSLP biologics and ITK-focused oral inhibitors.
  • Bosakitug (ATI-045) Phase 2 atopic dermatitis topline data targeted for 4Q 2026; positioned as higher potency with longer TSLP residence time.
  • ATI-052 bispecific TSLP x IL-4Rα Phase 1b proof-of-concept topline readouts in atopic dermatitis and asthma expected in 2H 2026; Phase 2b start slated for 4Q 2026.
  • Modzatinib (ATI-2138) Phase 2b initiation in lichen planus planned for 2H 2026; ATI-9494 IND submission planned for 2H 2026.
  • Cash position of $191 million as of 3/31/26; planned operations funded through 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.